Selective response to rituximab in a young child with MuSK-associated myasthenia gravis

Clinical features and evolution of juvenile myasthenia gravis in a French cohort

“…Recent studies have demonstrated the efficacy of rituximab in the treatment of MG in adults . In children, there are no studies on this subject and just a few case reports . In the 5 patients treated with rituximab in our cohort (including 3 with AChR antibodies), therapy was effective and tolerated.…”

“…It appears that the course of such a disease is generally worse, with a poor response to acetylcholinesterase inhibitors, more exacerbations or myasthenic crises, and the need for multimodal immunosuppressive therapy, as we encountered. Recent series in adults and children have found rituximab to have excellent efficacy in treating the MuSK forms, with high rates of complete remission . Although both MuSK‐positive patients in our cohort improved in response to rituximab, they continued to require high corticosteroid doses and plasmapheresis or azathioprine.…”

“…[56][57][58][59][60][61] In children, there are no studies on this subject and just a few case reports. 46,[62][63][64] In the 5 patients treated with rituximab in our cohort (including 3 with AChR antibodies), therapy was effective and tolerated.…”

“…Recent series in adults and children have found rituximab to have excellent efficacy in treating the MuSK forms, with high rates of complete remission. 45,46 Although both MuSK-positive patients in our cohort improved in response to rituximab, they continued to require high corticosteroid doses and plasmapheresis or azathioprine.…”

Rituximab treatment of myasthenia gravis: A systematic review

“…A total of 47 publications were reviewed, of which 28 were single case reports and 19 reporting 2 or more patients (range 2–22) . Only data available on unique cases from all published reports were included; data from publications that reported cases presented in earlier reports were excluded.…”